


List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3632416/publications.pdf Version: 2024-02-01



OINC XIE

#	Article	IF	CITATIONS
1	Combination of IL-34 and AFP improves the diagnostic value during the development of HBV related hepatocellular carcinoma. Clinical and Experimental Medicine, 2023, 23, 397-409.	3.6	5
2	PP2 protects from keratin mutation–associated liver injury and filament disruption via SRC kinase inhibition in male but not female mice. Hepatology, 2023, 77, 144-158.	7.3	4
3	Hepatitis B Surface Antigen Levels Can Be Used to Rule Out Cirrhosis in Hepatitis B e Antigen-Positive Chronic Hepatitis B: Results From the SONIC-B Study. Journal of Infectious Diseases, 2022, 225, 1967-1973.	4.0	11
4	Progression Rates by Age, Sex, Treatment, and Disease Activity by AASLD and EASL Criteria: Data for Precision Medicine. Clinical Gastroenterology and Hepatology, 2022, 20, 874-885.e4.	4.4	4
5	Longitudinal renal changes in chronic hepatitis B patients treated with entecavir versus TDF: a REAL-B study. Hepatology International, 2022, 16, 48-58.	4.2	7
6	Respiratory Muscle Training Reduces Respiratory Complications and Improves Swallowing Function After Stroke: A Systematic Review and Meta-Analysis. Archives of Physical Medicine and Rehabilitation, 2022, 103, 1179-1191.	0.9	12
7	Identification of a novel replication-competent hepatitis C virus variant that confers the sofosbuvir resistance. Antiviral Research, 2022, 197, 105224.	4.1	4
8	Acute-on-chronic liver failure in East Asia: an underestimated issue with limited data. Gut, 2022, 71, 445-446.	12.1	1
9	Genetic Variations of ALDH (rs671) Are Associated With the Persistence of HBV Infection Among the Chinese Han Population. Frontiers in Medicine, 2022, 9, 811639.	2.6	4
10	Long Non-coding RNA and mRNA Expression Change in Spinal Dorsal Horn After Exercise in Neuropathic Pain Rats. Frontiers in Molecular Neuroscience, 2022, 15, 865310.	2.9	0
11	Metabolic Risk Factors Are Associated with the Disease Severity and Prognosis of Hepatitis B Virus-Related Acute on Chronic Liver Failure. Gut and Liver, 2022, 16, 456-464.	2.9	2
12	Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition). Hepatobiliary Surgery and Nutrition, 2022, 11, 227-252.	1.5	55
13	A framework for quantifying the effects of transcranial magnetic stimulation on motor recovery from hemiparesis: corticomuscular network. Journal of Neural Engineering, 2022, 19, 026053.	3.5	4
14	A pilot study of synergy-based FES for upper-extremity poststroke rehabilitation. Neuroscience Letters, 2022, 780, 136621.	2.1	8
15	Letter to the editor: Exacerbation of autoimmune hepatitis after COVIDâ€19 vaccination. Hepatology, 2022, 75, 757-759.	7.3	24
16	Alteration of Bile Acids and Omega-6 PUFAs Are Correlated With the Progression and Prognosis of Drug-Induced Liver Injury. Frontiers in Immunology, 2022, 13, 772368.	4.8	9
17	M2 microglia-derived extracellular vesicles promote white matter repair and functional recovery via miR-23a-5p after cerebral ischemia in mice. Theranostics, 2022, 12, 3553-3573.	10.0	40
18	Efficacy and safety of bicyclol for treating patients with idiosyncratic acute drugâ€induced liver injury: A multicenter, randomized, phase <scp>II</scp> trial. Liver International, 2022, 42, 1803-1813.	3.9	7

#	Article	IF	CITATIONS
19	COVID-19 vaccines in patients with decompensated cirrhosis: a retrospective cohort on safety data and risk factors associated with unvaccinated status. Infectious Diseases of Poverty, 2022, 11, 56.	3.7	11
20	ABC: a novel algorithm to stratify decompensation risk in patients with compensated advanced chronic liver disease (CHESS2108): an international, multicenter cohort study. Hepatology International, 2022, 16, 1105-1115.	4.2	2
21	Tenofovir is superior to entecavir in reducing HCC for patients with HBV-related compensated cirrhosis at high HCC risk scores. Therapeutic Advances in Chronic Disease, 2022, 13, 204062232211027.	2.5	1
22	qHBsAg for the Identification of Liver Histological Abnormalities in HBeAg-Negative Chronic Hepatitis B Patients with Normal and Mildly Elevated ALT Levels. Canadian Journal of Gastroenterology and Hepatology, 2022, 2022, 1-7.	1.9	0
23	miR-552-3p modulates transcriptional activities of FXR and LXR to ameliorate hepatic glycolipid metabolism disorder. Journal of Hepatology, 2021, 74, 8-19.	3.7	37
24	Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patients. Hepatology International, 2021, 15, 71-81.	4.2	14
25	Laboratory-based Surveillance and Clinical Profile of Sporadic HEV Infection in Shanghai, China. Virologica Sinica, 2021, 36, 644-654.	3.0	6
26	Transcranial Focused Ultrasound Stimulation Improves Neurorehabilitation after Middle Cerebral Artery Occlusion in Mice. , 2021, 12, 50.		26
27	Autoimmune liver disease-associated serologic profiling in Chinese patients with acute hepatitis E virus infection. Immunologic Research, 2021, 69, 81-89.	2.9	5
28	A High Percentage of Patients Recovered From COVID-19 but Discharged With Abnormal Liver Function Tests. Frontiers in Physiology, 2021, 12, 642922.	2.8	18
29	Diagnostic Performance of FibroTouch Ultrasound Attenuation Parameter and Liver Stiffness Measurement in Assessing Hepatic Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Clinical and Translational Gastroenterology, 2021, 12, e00323.	2.5	22
30	Neutralizing monoclonal antibodies present new prospects to treat SARS-CoV-2 infections. Frontiers of Medicine, 2021, 15, 644-648.	3.4	0
31	3-year Treatment of Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate for Chronic HBV Infection in China. Journal of Clinical and Translational Hepatology, 2021, 000, 000-000.	1.4	7
32	Incidences and Determinants of Functional Cure During Entecavir or Tenofovir Disoproxil Fumarate for Chronic Hepatitis B. Journal of Infectious Diseases, 2021, 224, 1890-1899.	4.0	40
33	Repetitive Transcranial Magnetic Stimulation on the Affected Hemisphere Enhances Hand Functional Recovery in Subacute Adult Stroke Patients: A Randomized Trial. Frontiers in Aging Neuroscience, 2021, 13, 636184.	3.4	18
34	Tenofovir disoproxil fumarate in Chinese chronic hepatitis B patients: Results of a multicenter, double-blind, double-dummy, clinical trial at 96 weeks. World Journal of Clinical Cases, 2021, 9, 4690-4699.	0.8	0
35	External Validation of aMAP Hepatocellular Carcinoma Risk Score in Patients With Chronic Hepatitis B-Related Cirrhosis Receiving ETV or TDF Therapy. Frontiers in Medicine, 2021, 8, 677920.	2.6	11
36	Antimicrobial Resistance and Molecular Epidemiology of Uropathogenic Escherichia coli Isolated From Female Patients in Shanghai, China. Frontiers in Cellular and Infection Microbiology, 2021, 11, 653983.	3.9	15

#	Article	IF	CITATIONS
37	Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): A multicenter study. Journal of Hepatology, 2021, 75, 439-441.	3.7	82
38	A simple-to-use tool for predicting response to peginterferon in HBV DNA suppressed chronic hepatitis B patients in China. Antiviral Research, 2021, 194, 105163.	4.1	2
39	Dynamics of Hepatitis E Virus (HEV) Antibodies and Development of a Multifactorial Model To Improve the Diagnosis of HEV Infection in Resource-Limited Settings. Journal of Clinical Microbiology, 2021, 59, .	3.9	12
40	Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) and Viral Hepatitis. Journal of Clinical and Translational Hepatology, 2021, 10, 128-133.	1.4	5
41	Tenofovir disoproxil fumarate for multiple nucleos(t)ide analogues treatment failure hepatitis B: Is monotherapy enough?. Journal of Gastroenterology and Hepatology (Australia), 2021, , .	2.8	1
42	Application of Fatty Liver Inhibition of Progression Algorithm and Steatosis, Activity, and Fibrosis Score to Assess the Impact of Non-Alcoholic Fatty Liver on Untreated Chronic Hepatitis B Patients. Frontiers in Cellular and Infection Microbiology, 2021, 11, 733348.	3.9	5
43	Real-World Effectiveness From the Asia Pacific Rim Liver Consortium for HBV Risk Score for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated With Oral Antiviral Therapy. Journal of Infectious Diseases, 2020, 221, 389-399.	4.0	58
44	Association Between Negative Results From Tests for HBV DNA and RNA and Durability of Response After Discontinuation of Nucles(t)ide Analogue Therapy. Clinical Gastroenterology and Hepatology, 2020, 18, 719-727.e7.	4.4	72
45	Modulation of bile acid profile by gut microbiota in chronic hepatitis B. Journal of Cellular and Molecular Medicine, 2020, 24, 2573-2581.	3.6	36
46	Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B. American Journal of Gastroenterology, 2020, 115, 271-280.	0.4	72
47	Interleukin-22 ameliorates acute-on-chronic liver failure by reprogramming impaired regeneration pathways in mice. Journal of Hepatology, 2020, 72, 736-745.	3.7	109
48	Anti-viral effect in chronic hepatitis B patients with normal or mildly elevated alanine aminotransferase. Antiviral Research, 2020, 184, 104953.	4.1	8
49	Automated functional electrical stimulation training system for upper-limb function recovery in poststroke patients. Medical Engineering and Physics, 2020, 84, 174-183.	1.7	10
50	aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. Journal of Hepatology, 2020, 73, 1368-1378.	3.7	158
51	<p>Efflux Pump AcrAB Confers Decreased Susceptibility to Piperacillin–Tazobactam and Ceftolozane–Tazobactam in Tigecycline-Non-Susceptible Klebsiella pneumoniae</p> . Infection and Drug Resistance, 2020, Volume 13, 4309-4319.	2.7	10
52	Multicenter prospective study to validate a new transient elastography device for staging liver fibrosis in patients with chronic hepatitis B. Journal of Digestive Diseases, 2020, 21, 519-525.	1.5	11
53	Sentinel surveillance strategies for early detection of coronavirus disease in fever clinics: experience from China. Epidemiology and Infection, 2020, 148, e205.	2.1	5
54	Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ, The, 2020, 369, m1849.	6.0	811

#	Article	IF	CITATIONS
55	Effects of transcranial direct current stimulation with virtual reality on upper limb function in patients with ischemic stroke: a randomized controlled trial. Journal of NeuroEngineering and Rehabilitation, 2020, 17, 73.	4.6	31
56	Circulating Receptor-Interacting Protein Kinase 3 Are Increased in HBV Patients With Acute-on-Chronic Liver Failure and Are Associated With Clinical Outcome. Frontiers in Physiology, 2020, 11, 526.	2.8	7
57	Combination of inflammatory score/liver function and AFP improves the diagnostic accuracy of HBVâ€related hepatocellular carcinoma. Cancer Medicine, 2020, 9, 3057-3069.	2.8	23
58	Combining Hepatitis B Virus RNA and Hepatitis B Core–Related Antigen: Guidance for Safely Stopping Nucleos(t)ide Analogues in Hepatitis B e Antigen–Positive Patients With Chronic Hepatitis B. Journal of Infectious Diseases, 2020, 222, 611-618.	4.0	50
59	Rapidly decreased HBV RNA predicts responses of pegylated interferons in HBeAg-positive patients: a longitudinal cohort study. Hepatology International, 2020, 14, 212-224.	4.2	26
60	Final analysis of the international observational S-Collate study of peginterferon alfa-2a in patients with chronic hepatitis B. PLoS ONE, 2020, 15, e0230893.	2.5	2
61	Histological Outcome of Fuzheng Huayu plus Entecavir Combination Therapy in Chronic Hepatitis B Patients with Significant Liver Fibrosis. Journal of Clinical and Translational Hepatology, 2020, 8, 1-8.	1.4	11
62	The Use of NACSELD and EASL-CLIF Classification Systems of ACLF in the Prediction of Prognosis in Hospitalized Patients With Cirrhosis. American Journal of Gastroenterology, 2020, 115, 2026-2035.	0.4	37
63	Combined effect of repetitive transcranial magnetic stimulation and physical exercise on cortical plasticity. Neural Regeneration Research, 2020, 15, 1986.	3.0	22
64	Bacterial infection triggers and complicates acute-on-chronic liver failure in patients with hepatitis B virus-decompensated cirrhosis: A retrospective cohort study. World Journal of Gastroenterology, 2020, 26, 645-656.	3.3	6
65	Peginterferon and Entecavir Combination Therapy Improves Outcome of Non–Early Response Hepatitis B e Antigen–Positive Patients. Open Forum Infectious Diseases, 2020, 7, ofaa462.	0.9	3
66	Rapamycin Increases Collateral Circulation in Rodent Brain after Focal Ischemia as detected by Multiple Modality Dynamic Imaging. Theranostics, 2019, 9, 4923-4934.	10.0	28
67	Long-Term Bone Regeneration Enabled by a Polyhedral Oligomeric Silsesquioxane (POSS)-Enhanced Biodegradable Hydrogel. ACS Biomaterials Science and Engineering, 2019, 5, 4612-4623.	5.2	33
68	Construction and characterization of Genotype-3 hepatitis C virus replicon revealed critical genotype-3-specific polymorphism for drug resistance and viral fitness. Antiviral Research, 2019, 171, 104612.	4.1	6
69	Low hepatitis B surface antigen and HBV DNA levels predict response to the addition of pegylated interferon to entecavir in hepatitis B e antigen positive chronic hepatitis B. Alimentary Pharmacology and Therapeutics, 2019, 49, 448-456.	3.7	20
70	The impact of HBV flare on the outcome of HBVâ€related decompensated cirrhosis patients with bacterial infection. Liver International, 2019, 39, 1943-1953.	3.9	17
71	Sequential combination therapy with interferon, interleukin-2 and therapeutic vaccine in entecavir-suppressed chronic hepatitis B patients: the Endeavor study. Hepatology International, 2019, 13, 573-586.	4.2	29
72	Incidence and Etiology of Drug-Induced Liver Injury in Mainland China. Gastroenterology, 2019, 156, 2230-2241.e11.	1.3	346

#	Article	IF	CITATIONS
73	Sustained serological and complete responses in HBeAg-positive patients treated with Peginterferon alfa-2b: a 6-year long-term follow-up of a multicenter, randomized, controlled trial in China. BMC Gastroenterology, 2019, 19, 65.	2.0	6
74	Variable High-Frequency Deep Brain Stimulation of the Subthalamic Nucleus for Speech Disorders in Parkinson's Disease: A Case Report. Frontiers in Neurology, 2019, 10, 379.	2.4	7
75	Comparison of the efficacy of sofosbuvir plus ribavirin in Chinese patients with genotype 3a or 3b HCV infection. Journal of Medical Virology, 2019, 91, 1313-1318.	5.0	12
76	IPS-1 polymorphisms in regulating interferon response in HBV infection. BioScience Trends, 2019, 13, 130-135.	3.4	2
77	Optimisation of the use of APRI and FIB-4 to rule out cirrhosis in patients with chronic hepatitis B: results from the SONIC-B study. The Lancet Gastroenterology and Hepatology, 2019, 4, 538-544.	8.1	49
78	Long-term efficacy and safety of tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B: 5-year results. Hepatology International, 2019, 13, 260-269.	4.2	18
79	Serum keratinâ€18 fragments as cell death biomarker in association with disease progression and prognosis in hepatitis B virusâ€related cirrhosis. Journal of Viral Hepatitis, 2019, 26, 835-845.	2.0	8
80	Comparison of FibroTouch and FibroScan for staging fibrosis in chronic liver disease: Single-center prospective study. Digestive and Liver Disease, 2019, 51, 1323-1329.	0.9	30
81	Subtype-Specific Prevalence of Hepatitis C Virus NS5A Resistance Associated Substitutions in Mainland China. Frontiers in Microbiology, 2019, 10, 535.	3.5	17
82	Genome-wide Association Study Identifies Genetic Variants Associated With Early and Sustained Response to (Pegylated) Interferon in Chronic Hepatitis B Patients: The GIANT-B Study. Clinical Infectious Diseases, 2019, 69, 1969-1979.	5.8	21
83	The Effects of Combined Low Frequency Repetitive Transcranial Magnetic Stimulation and Motor Imagery on Upper Extremity Motor Recovery Following Stroke. Frontiers in Neurology, 2019, 10, 96.	2.4	16
84	Unsatisfying antiviral therapeutic effect in patients with mother-to-child transmissed chronic hepatitis B virus infection. Chinese Medical Journal, 2019, 132, 2647-2656.	2.3	2
85	A randomized, double-blind, double-dummy, controlled, multicenter study of Qingzhong (tenofovir) Tj ETQq1 1 C 2019, 98, e16778.).784314 1.0	rgBT /Overloo 2
86	Serotype Distribution, Antimicrobial Susceptibility, and Multilocus Sequencing Type (MLST) of Streptococcus pneumoniae From Adults of Three Hospitals in Shanghai, China. Frontiers in Cellular and Infection Microbiology, 2019, 9, 407.	3.9	14
87	Long Non-coding RNA NEAT1 Alleviates Acute-on-Chronic Liver Failure Through Blocking TRAF6 Mediated Inflammatory Response. Frontiers in Physiology, 2019, 10, 1503.	2.8	13
88	Longâ€ŧerm followâ€up of patients treated with entecavir and peginterferon addâ€on therapy for <scp>HB</scp> eAgâ€positive chronic hepatitis B infection: <scp>ARES</scp> longâ€ŧerm followâ€up. Journal of Viral Hepatitis, 2019, 26, 109-117.	2.0	20
89	Sofosbuvir–velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial. The Lancet Gastroenterology and Hepatology, 2019, 4, 127-134.	8.1	83
90	Cost-effectiveness of novel regimens for Chinese patients with chronic hepatitis C. Current Medical Research and Opinion, 2019, 35, 847-857.	1.9	8

#	Article	IF	CITATIONS
91	Management Algorithm for Interrupting Mother-to-Child Transmission of Hepatitis B Virus. Clinical Gastroenterology and Hepatology, 2019, 17, 1929-1936.e1.	4.4	51
92	A Potential Functional Cure in Chinese HBeAg-negative Chronic Hepatitis B Patients Treated with Peg-interferon Alpha-2a. Journal of Clinical and Translational Hepatology, 2019, 7, 1-9.	1.4	4
93	Efficacy and Safety of All-oral, 12-week Ravidasvir Plus Ritonavir-boosted Danoprevir and Ribavirin in Treatment-naÃ-ve Noncirrhotic HCV Genotype 1 Patients: Results from a Phase 2/3 Clinical Trial in China. Journal of Clinical and Translational Hepatology, 2019, 7, 1-8.	1.4	12
94	Real-World Clinical Outcomes among Individuals with Chronic HCV Infection in China: CCgenos Study. Antiviral Therapy, 2019, 24, 473-483.	1.0	4
95	Hepatitis C virus cure with direct-acting antivirals: Clinical, economic, societal and patient value for China. World Journal of Hepatology, 2019, 11, 421-441.	2.0	12
96	Baseline Characteristics and Treatment Patterns of the Patients Recruited to the China Registry of Hepatitis B. Journal of Clinical and Translational Hepatology, 2019, X, 1-7.	1.4	8
97	The Effectiveness of Acupuncture for Osteoporosis: A Systematic Review and Meta-Analysis. The American Journal of Chinese Medicine, 2018, 46, 489-513.	3.8	29
98	Ledipasvir/sofosbuvir for treatment-naive and treatment-experienced Chinese patients with genotype 1 HCV: an open-label, phase 3b study. Hepatology International, 2018, 12, 126-132.	4.2	19
99	Tolvaptan in Chinese cirrhotic patients with ascites: A randomized, placeboâ€controlled phase 2 trial. Journal of Digestive Diseases, 2018, 19, 144-154.	1.5	7
100	Sofosbuvir plus ribavirin with or without peginterferon for the treatment of hepatitis C virus: Results from a phase 3b study in China. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 1168-1176.	2.8	17
101	Correlation between hepatic human males absent on the first (hMOF) and viral persistence in chronic hepatitis B patients. Cell and Bioscience, 2018, 8, 14.	4.8	4
102	Effect of hepatitis B virus subgenotype on antiviral response in nucleosideâ€treated hepatitis B envelope antigenâ€positive patients. Hepatology Research, 2018, 48, 134-143.	3.4	12
103	Association of baseline vitamin D level with genetic determinants and virologic response in patients with chronic hepatitis B. Hepatology Research, 2018, 48, E213-E221.	3.4	19
104	Entecavir add-on or switch-to pegylated interferon improves HBsAg clearance in HBe antigen negative chronic hepatitis B patients. Infection and Drug Resistance, 2018, Volume 11, 2001-2009.	2.7	14
105	Interferon-based treatment is superior to nucleos(t)ide analog in reducing HBV-related hepatocellular carcinoma for chronic hepatitis B patients at high risk. Expert Opinion on Biological Therapy, 2018, 18, 1085-1094.	3.1	24
106	Enhancer of zeste homolog 2-catalysed H3K27 trimethylation plays a key role in acute-on-chronic liver failure via TNF-mediated pathway. Cell Death and Disease, 2018, 9, 590.	6.3	25
107	Combination of entecavir with thymosin alpha-1 in HBV-related compensated cirrhosis: a prospective multicenter randomized open-label study. Expert Opinion on Biological Therapy, 2018, 18, 61-69.	3.1	17
108	A cross-sectional assessment of health-related quality of life in Chinese patients with chronic hepatitis c virus infection with EQ-5D. Health and Quality of Life Outcomes, 2018, 16, 124.	2.4	28

#	Article	IF	CITATIONS
109	HCV phylogenetic signature and prevalence of pretreatment NS5A and NS5B NI-Resistance associated substitutions in HCV-Infected patients in Mainland China. Antiviral Research, 2018, 158, 178-184.	4.1	17
110	Enhanced autophagy contributes to protective effects of IL-22 against acetaminophen-induced liver injury. Theranostics, 2018, 8, 4170-4180.	10.0	48
111	HBsAg Loss with Peg-interferon Alfa-2a in Hepatitis B Patients with Partial Response to Nucleos(t)ide Analog: New Switch Study. Journal of Clinical and Translational Hepatology, 2018, 6, 1-10.	1.4	82
112	Daclatasvir plus asunaprevir in treatment-naÃ⁻ve patients with hepatitis C virus genotype 1b infection. World Journal of Gastroenterology, 2018, 24, 1361-1372.	3.3	6
113	Effects of miR-146a on the osteogenesis of adipose-derived mesenchymal stem cells and bone regeneration. Scientific Reports, 2017, 7, 42840.	3.3	87
114	CSH guidelines for the diagnosis and treatment of drug-induced liver injury. Hepatology International, 2017, 11, 221-241.	4.2	206
115	Pegylated Interferon Alfa-2b Add-on Treatment in Hepatitis B Virus Envelope Antigen-Positive Chronic Hepatitis B Patients Treated with Nucleos(t)ide Analogue: A Randomized, Controlled Trial (PEGON). Journal of Infectious Diseases, 2017, 215, 1085-1093.	4.0	46
116	The 2.8ÂÃ Electron Microscopy Structure of Adeno-Associated Virus-DJ Bound by a Heparinoid Pentasaccharide. Molecular Therapy - Methods and Clinical Development, 2017, 5, 1-12.	4.1	30
117	Younger trend of cirrhosis incidence in genotype 3 HCV infected patients in Eastern China. Journal of Medical Virology, 2017, 89, 1973-1980.	5.0	10
118	Algorithm of Golgi protein 73 and liver stiffness accurately diagnoses significant fibrosis in chronic <scp>HBV</scp> infection. Liver International, 2017, 37, 1612-1621.	3.9	37
119	MBC-Modified Î ² -TCP Scaffold Promotes Mesenchymal Stem Cells Adhesion and Osteogenic Differentiation via a FAK/MAPK Signaling Pathway. ACS Applied Materials & Interfaces, 2017, 9, 30283-30296.	8.0	52
120	Analysis of immunological mechanisms exerted by HBsAg-HBIG therapeutic vaccine combined with Adefovir in chronic hepatitis B patients. Human Vaccines and Immunotherapeutics, 2017, 13, 1989-1996.	3.3	14
121	Realâ€world treatment patterns and clinical outcomes of HCV treatmentâ€naive patients in China: an interim analysis from the CCgenos study. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 244-252.	2.8	27
122	Persistently elevated circulating Th22 reversely correlates with prognosis in HBVâ€related acuteâ€onâ€chronic liver failure. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 677-686.	2.8	18
123	Evaluation of Functional Correlation of Task-Specific Muscle Synergies with Motor Performance in Patients Poststroke. Frontiers in Neurology, 2017, 8, 337.	2.4	38
124	Development and Feasibility Assessment of a Rotational Orthosis for Walking with Arm Swing. Frontiers in Neuroscience, 2017, 11, 32.	2.8	12
125	Constraint-induced aphasia therapy in post-stroke aphasia rehabilitation: A systematic review and meta-analysis of randomized controlled trials. PLoS ONE, 2017, 12, e0183349.	2.5	40
126	Genetic variations of NTCP are associated with susceptibility to HBV infection and related hepatocellular carcinoma. Oncotarget, 2017, 8, 105407-105424.	1.8	23

#	Article	IF	CITATIONS
127	Neural computational modeling reveals a major role of corticospinal gating of central oscillations in the generation of essential tremor. Neural Regeneration Research, 2017, 12, 2035.	3.0	7
128	Electrospun silk fibroin/poly(lactide-co-ε-caprolactone) nanofibrous scaffolds for bone regeneration. International Journal of Nanomedicine, 2016, 11, 1483.	6.7	35
129	High-Throughput Screening for Drugs that Modulate Intermediate Filament Proteins. Methods in Enzymology, 2016, 568, 163-185.	1.0	16
130	Atg7 Knockdown Augments Concanavalin A-Induced Acute Hepatitis through an ROS-Mediated p38/MAPK Pathway. PLoS ONE, 2016, 11, e0149754.	2.5	37
131	Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World Data. PLoS ONE, 2016, 11, e0155934.	2.5	34
132	Correlation between circulating miRâ€122 and prognosis of chronic HBVâ€related liver failure. Journal of Digestive Diseases, 2016, 17, 334-339.	1.5	17
133	Enhanced Physiochemical and Mechanical Performance of Chitosanâ€Grafted Graphene Oxide for Superior Osteoinductivity. Advanced Functional Materials, 2016, 26, 1085-1097.	14.9	118
134	Female gender lost protective effect against disease progression in elderly patients with chronic hepatitis B. Scientific Reports, 2016, 6, 37498.	3.3	13
135	A five years study of antiviral effect of entecavir in Chinese chronic hepatitis B patients. Scientific Reports, 2016, 6, 28779.	3.3	3
136	Response-guided peginterferon therapy in patients with HBeAg-positive chronic hepatitis B: A randomized controlled study. Journal of Hepatology, 2016, 65, 674-682.	3.7	36
137	Serum hepatocyte apoptosis biomarker predicts the presence of significant histological lesion in chronic hepatitis B virus infection. Digestive and Liver Disease, 2016, 48, 1463-1470.	0.9	9
138	PEGylated poly(glycerol sebacate)-modified calcium phosphate scaffolds with desirable mechanical behavior and enhanced osteogenic capacity. Acta Biomaterialia, 2016, 44, 110-124.	8.3	67
139	A phase 3, openâ€label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 1860-1867.	2.8	32
140	SUMO-specific protease 3 is a key regulator for hepatic lipid metabolism in non-alcoholic fatty liver disease. Scientific Reports, 2016, 6, 37351.	3.3	11
141	Characteristics, Diagnosis and Prognosis of Acute-on-Chronic Liver Failure in Cirrhosis Associated to Hepatitis B Scientific Reports, 2016, 6, 25487.	3.3	125
142	Simeprevir plus peginterferon/ribavirin for HCV genotype 1â€infected treatmentâ€naÃ⁻ve patients in China and South Korea. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 912-920.	2.8	8
143	The role of miR-135-modified adipose-derived mesenchymal stem cells in bone regeneration. Biomaterials, 2016, 75, 279-294.	11.4	92
144	Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues. Gut, 2016, 65, 313-320.	12.1	112

#	Article	IF	CITATIONS
145	Randomized clinical trial: Nucleos(t)ide analogues improved survival of CHB-related HCC patients via reducing severity and progression of malignancy. Oncotarget, 2016, 7, 58553-58562.	1.8	3
146	A regulatory loop containing miR-26a, CSK3β and C/EBPα regulates the osteogenesis of human adipose-derived mesenchymal stem cells. Scientific Reports, 2015, 5, 15280.	3.3	36
147	Composition and Interactions of Hepatitis B Virus Quasispecies Defined the Virological Response During Telbivudine Therapy. Scientific Reports, 2015, 5, 17123.	3.3	14
148	Circulating cell death biomarker: good candidates of prognostic indicator for patients with hepatitis B virus related acute-on-chronic liver failure. Scientific Reports, 2015, 5, 14240.	3.3	22
149	Long-Term Telbivudine Treatment Results in Resolution of Liver Inflammation and Fibrosis in Patients with Chronic Hepatitis B. Advances in Therapy, 2015, 32, 727-741.	2.9	19
150	Identification of acetyltransferase genes (HAT1 and KAT8) regulating HBV replication by RNAi screening. Cell and Bioscience, 2015, 5, 66.	4.8	10
151	PKC412 normalizes mutationâ€related keratin filament disruption and hepatic injury in mice by promoting keratin–myosin binding. Hepatology, 2015, 62, 1858-1869.	7.3	26
152	MicroRNA-224 Induces G1/S Checkpoint Release in Liver Cancer. Journal of Clinical Medicine, 2015, 4, 1713-1728.	2.4	25
153	Validation of Ten Noninvasive Diagnostic Models for Prediction of Liver Fibrosis in Patients with Chronic Hepatitis B. PLoS ONE, 2015, 10, e0144425.	2.5	20
154	The influence of frame alignment with dose compensation on the quality of single particle reconstructions. Journal of Structural Biology, 2015, 192, 196-203.	2.8	30
155	Association of IPS1 polymorphisms with peginterferon efficacy in chronic hepatitis B with HBeAg-positive in the Chinese population. Infection, Genetics and Evolution, 2015, 31, 161-168.	2.3	5
156	Submassive hepatic necrosis distinguishes HBV-associated acute on chronic liver failure from cirrhotic patients with acute decompensation. Journal of Hepatology, 2015, 63, 50-59.	3.7	76
157	Protective effect of Th22 cells and intrahepatic IL-22 in drug induced hepatocellular injury. Journal of Hepatology, 2015, 63, 148-155.	3.7	48
158	Characterization of human ethmoid sinus mucosa derived mesenchymal stem cells (hESMSCs) and the application of hESMSCs cell sheets in bone regeneration. Biomaterials, 2015, 66, 67-82.	11.4	56
159	A Randomized, Open-Label Clinical Study of Combined Pegylated Interferon Alfa-2a (40KD) and Entecavir Treatment for Hepatitis B "e" Antigen-Positive Chronic Hepatitis B. Clinical Infectious Diseases, 2014, 59, 1714-1723.	5.8	79
160	Effects of miR-31 on the osteogenesis of human mesenchymal stem cells. Biochemical and Biophysical Research Communications, 2014, 446, 98-104.	2.1	70
161	Peginterferon alfa-2b in the treatment of Chinese patients with HBeAg-positive chronic hepatitis B: A randomized trial. Journal of Clinical Virology, 2014, 61, 509-516.	3.1	14
162	Effects of let-7b and TLX on the proliferation and differentiation of retinal progenitor cells in vitro. Scientific Reports, 2014, 4, 6671.	3.3	47

#	Article	IF	CITATIONS
163	Electron microscopy analysis of a disaccharide analog complex reveals receptor interactions of adeno-associated virus. Journal of Structural Biology, 2013, 184, 129-135.	2.8	15
164	A Novel Estimation of the Impact of Treatment with Entecavir on Long-Term Mortality, Morbidity, and Health Care Costs of Chronic Hepatitis B in China. Value in Health Regional Issues, 2013, 2, 48-56.	1.2	10
165	Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. Hepatology, 2013, 58, 872-880.	7.3	201
166	The development of an exoskeleton robot for co-manipulation of human upper limb movement. , 2012, ,		2
167	Development of human-machine interface for teleoperation of a mobile manipulator. International Journal of Control, Automation and Systems, 2012, 10, 1225-1231.	2.7	18
168	Structure–function analysis of receptor-binding in adeno-associated virus serotype 6 (AAV-6). Virology, 2011, 420, 10-19.	2.4	58
169	Establishing a metabolomic model for the prognosis of hepatitis B virus-induced acute-on-chronic liver failure treated with different liver support systems. Metabolomics, 2011, 7, 400-412.	3.0	14
170	Patients with chronic hepatitis B infection display deficiency of plasmacytoid dendritic cells with reduced expression of TLR9. Microbes and Infection, 2009, 11, 515-523.	1.9	78
171	Crystallization and preliminary X-ray structural studies of adeno-associated virus serotype 6. Acta Crystallographica Section F: Structural Biology Communications, 2008, 64, 1074-1078.	0.7	17
172	Activity identification of chimeric anti-caspase-3 mRNA hammerhead ribozymein vitro andin vivo. Science in China Series C: Life Sciences, 2001, 44, 618-627.	1.3	4
173	240â€week Entecavir maleate treatment in Chinese chronic hepatitis B predominantly genotype B or C.	2.0	1